410 related articles for article (PubMed ID: 33140540)
1. A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma.
Wright KD; Yao X; London WB; Kao PC; Gore L; Hunger S; Geyer R; Cohen KJ; Allen JC; Katzenstein HM; Smith A; Boklan J; Nazemi K; Trippett T; Karajannis M; Herzog C; Destefano J; Direnzo J; Pietrantonio J; Greenspan L; Cassidy D; Schissel D; Perentesis J; Basu M; Mizuno T; Vinks AA; Prabhu SP; Chi SN; Kieran MW
Pediatr Blood Cancer; 2021 Feb; 68(2):e28787. PubMed ID: 33140540
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study.
Ullrich NJ; Prabhu SP; Reddy AT; Fisher MJ; Packer R; Goldman S; Robison NJ; Gutmann DH; Viskochil DH; Allen JC; Korf B; Cantor A; Cutter G; Thomas C; Perentesis JP; Mizuno T; Vinks AA; Manley PE; Chi SN; Kieran MW
Neuro Oncol; 2020 Oct; 22(10):1527-1535. PubMed ID: 32236425
[TBL] [Abstract][Full Text] [Related]
3. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.
Wahl M; Chang SM; Phillips JJ; Molinaro AM; Costello JF; Mazor T; Alexandrescu S; Lupo JM; Nelson SJ; Berger M; Prados M; Taylor JW; Butowski N; Clarke JL; Haas-Kogan D
Cancer; 2017 Dec; 123(23):4631-4639. PubMed ID: 28759109
[TBL] [Abstract][Full Text] [Related]
4. Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial.
Haas-Kogan DA; Aboian MS; Minturn JE; Leary SES; Abdelbaki MS; Goldman S; Elster JD; Kraya A; Lueder MR; Ramakrishnan D; von Reppert M; Liu KX; Rokita JL; Resnick AC; Solomon DA; Phillips JJ; Prados M; Molinaro AM; Waszak SM; Mueller S
J Clin Oncol; 2024 Feb; 42(4):441-451. PubMed ID: 37978951
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.
Bouffet E; Jakacki R; Goldman S; Hargrave D; Hawkins C; Shroff M; Hukin J; Bartels U; Foreman N; Kellie S; Hilden J; Etzl M; Wilson B; Stephens D; Tabori U; Baruchel S
J Clin Oncol; 2012 Apr; 30(12):1358-63. PubMed ID: 22393086
[TBL] [Abstract][Full Text] [Related]
6. Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer.
Fukudo M; Ishibashi K; Kitada M
Invest New Drugs; 2021 Dec; 39(6):1707-1715. PubMed ID: 34041638
[TBL] [Abstract][Full Text] [Related]
7. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
Gorsi HS; Khanna PC; Tumblin M; Yeh-Nayre L; Milburn M; Elster JD; Crawford JR
Pediatr Blood Cancer; 2018 Sep; 65(9):e27234. PubMed ID: 29750399
[TBL] [Abstract][Full Text] [Related]
8. A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG).
Yalon M; Rood B; MacDonald TJ; McCowage G; Kane R; Constantini S; Packer RJ
Pediatr Blood Cancer; 2013 Jan; 60(1):71-6. PubMed ID: 22434731
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in recurrent high-grade pediatric gliomas.
Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
[TBL] [Abstract][Full Text] [Related]
10. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
Ma DJ; Galanis E; Anderson SK; Schiff D; Kaufmann TJ; Peller PJ; Giannini C; Brown PD; Uhm JH; McGraw S; Jaeckle KA; Flynn PJ; Ligon KL; Buckner JC; Sarkaria JN
Neuro Oncol; 2015 Sep; 17(9):1261-9. PubMed ID: 25526733
[TBL] [Abstract][Full Text] [Related]
12. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
13. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F
J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558
[TBL] [Abstract][Full Text] [Related]
14. First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma.
Wen PY; Cloughesy TF; Olivero AG; Morrissey KM; Wilson TR; Lu X; Mueller LU; Coimbra AF; Ellingson BM; Gerstner E; Lee EQ; Rodon J
Clin Cancer Res; 2020 Apr; 26(8):1820-1828. PubMed ID: 31937616
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors.
Santana VM; Sahr N; Tatevossian RG; Jia S; Campagne O; Sykes A; Stewart CF; Furman WL; McGregor LM
Cancer; 2020 Apr; 126(8):1749-1757. PubMed ID: 31967673
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.
Banerjee A; Jakacki RI; Onar-Thomas A; Wu S; Nicolaides T; Young Poussaint T; Fangusaro J; Phillips J; Perry A; Turner D; Prados M; Packer RJ; Qaddoumi I; Gururangan S; Pollack IF; Goldman S; Doyle LA; Stewart CF; Boyett JM; Kun LE; Fouladi M
Neuro Oncol; 2017 Aug; 19(8):1135-1144. PubMed ID: 28339824
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
Hurwitz CA; Strauss LC; Kepner J; Kretschmar C; Harris MB; Friedman H; Kun L; Kadota R
J Pediatr Hematol Oncol; 2001; 23(5):277-81. PubMed ID: 11464982
[TBL] [Abstract][Full Text] [Related]
19. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
Shih KC; Chowdhary S; Rosenblatt P; Weir AB; Shepard GC; Williams JT; Shastry M; Burris HA; Hainsworth JD
J Neurooncol; 2016 Sep; 129(2):281-8. PubMed ID: 27311730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]